drugset

drugset / Trial / NCT03719768

Avelumab With Radiotherapy in Patients With Leptomeningeal Disease

NCT03719768 ↗

Phase 1 Completed 16 enrolled H. Lee Moffitt Cancer Center and Research Institute Pfizer · collab

NaSingle-groupOpen-labelTreatment

Summary

This study is to find a safe dose of the combination of Avelumab and Whole Brain Radiotherapy (WBRT) in patients with Leptomeningeal Disease.

Timeline

Start: 2019-06-10
Primary completion: 2022-07-19
Completion: 2024-08-21

Publications

Pina Y, Law V, Sahebjam S, Tran N, Siddarajappa N, Li J, Mo Q, Phadke MS, Arrington J, Macaulay R, Mokhtari S, Evernden B, Ahmed KA, Smalley I, Yu M, Smalley KSM, Forsyth PA. Phase IB study of Avelumab and whole brain radiotherapy in patients with leptomeningeal disease from solid tumors: Results and molecular analyses. Neuro Oncol. 2025 Dec 1;27(12):3237-3249. doi: 10.1093/neuonc/noaf183.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Avelumab	Monoclonal antibody	800 mg	Intravenous

Indications